Our progress across all these fronts will hopefully earn high commendation from the Medical Council of Hong Kong when they visit us in September for a re-accreditation exercise. We are primed to deliver clear information and messages about the strengths of our programmes, on the back of our success with the Academic Review and the reaccreditation of the BPharm programme by the Pharmacy and Poisons Board in March. I welcome the coming visit because it will offer a fresh set of eyes on our progress. I hope to report positive feedback, as well as recommendations for growth, when the exercise is completed. 21
RkJQdWJsaXNoZXIy Mzg4NDg0